Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Evens

Showing results (201-210 of 253) with videos related to

Pageof 26
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2014
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapyJ S Abramson, T Feldman, A R Kroll-Desrosiers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphomaJane N Winter, David J Inwards, Stewart Spies, et al.
British Journal of Haematology|January 30, 2013
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496Andrew M Evens, Fangxin Hong, Leo I Gordon, et al.
Frontiers in Oncology|November 12, 2021
Oncogenic Integration of Nucleotide Metabolism <i>via</i> Fatty Acid Synthase in Non-Hodgkin LymphomaDashnamoorthy Ravi, Afshin Beheshti, Nasséra Abermil, et al.
Blood Advances|September 9, 2022
Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphomaPamela B Allen, Xinyan Lu, Qing Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2020
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408Andrew M Evens, Fangxin Hong, Thomas M Habermann, et al.
Leukemia & Lymphoma|October 3, 2018
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER studyJeff P Sharman, Andres Forero-Torres, Luciano J Costa, et al.
The New England Journal of Medicine|October 2, 2004
Pure red-cell aplasia and epoetin therapyCharles L Bennett, Stefano Luminari, Allen R Nissenson, et al.
Blood|July 24, 2019
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphomaDeborah M Stephens, Hongli Li, Heiko Schöder, et al.
Blood|May 3, 2014
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse eventMitul D Gandhi, Andrew M Evens, Timothy S Fenske, et al.
Pageof 26

Showing results (201-210 of 253) with videos related to

Sort By:
Pageof 26
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2014
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapyJ S Abramson, T Feldman, A R Kroll-Desrosiers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphomaJane N Winter, David J Inwards, Stewart Spies, et al.
British Journal of Haematology|January 30, 2013
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496Andrew M Evens, Fangxin Hong, Leo I Gordon, et al.
Frontiers in Oncology|November 12, 2021
Oncogenic Integration of Nucleotide Metabolism <i>via</i> Fatty Acid Synthase in Non-Hodgkin LymphomaDashnamoorthy Ravi, Afshin Beheshti, Nasséra Abermil, et al.
Blood Advances|September 9, 2022
Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphomaPamela B Allen, Xinyan Lu, Qing Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2020
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408Andrew M Evens, Fangxin Hong, Thomas M Habermann, et al.
Leukemia & Lymphoma|October 3, 2018
Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER studyJeff P Sharman, Andres Forero-Torres, Luciano J Costa, et al.
The New England Journal of Medicine|October 2, 2004
Pure red-cell aplasia and epoetin therapyCharles L Bennett, Stefano Luminari, Allen R Nissenson, et al.
Blood|July 24, 2019
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphomaDeborah M Stephens, Hongli Li, Heiko Schöder, et al.
Blood|May 3, 2014
Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse eventMitul D Gandhi, Andrew M Evens, Timothy S Fenske, et al.
Pageof 26